- Glucocorticoid-remediable Aldosteronism (GRA) is a rare form of primary aldosteronism in which aldosterone secretion is solely under the control of Adrenocorticotropic hormone (ACTH). GRA is caused by a chimeric gene in which the the ACTH- responsive 5'-promoter of the 11Beta-hydroxylase gene is fused to coding sequences of the aldosterone synthase gene. This results in ectopic expression of aldosterone synthase activity in zona fasciculata cells of the adrenal cortex under the regulation of ACTH, with resultant hyperaldosteronism and suppression of angiotensin II-stimulated aldosterone production in the zona glomerulosa.
The most common presentation of GRA is the discovery of asymptomatic severe hypertension, especially in infancy or early adulthood. A strong family history of hypertension, often associated with early death of affected family members due to cerebrovascualr accidents, characteristically is seen in some GRA families. An important clinical clue is the age of onset of hypertension, with GRA patients typically diagnosed with high blood pressure as children; this is in contrast to patients with other mineralocorticoid excess states, such as aldosterone producing adenomas and idiopathic hyperplasia, who usually are diagnosed in the third through sixth decades of life. As expected plasma-renin activity is typically very low, and plasma aldosterone concentration high in those with GRA. Hypokalemia is often seen, but not the norm.
GRA, a hereditary cause of hypertension, is passed on in an autosomal dominant inheritance pattern. Genetic testing is 100% sensitive and specific for the diagnosis of GRA. (See Screening Information for information on how to have a patient screened). A dexamethasone suppression test (DST) is highly indicative of GRA, and easy to administer, but lacks the absolute specificity of the genetic test. (see Publications, "Evaluation of the dexamethasone suppression test for the diagnosis of GRA", Litchfield, et al.) The DST should be used in patients with biochemical primary hyperaldosteronism, who have a suggestive clinical history, and negative CT imaging of the adrenals. However, a positive DST should not displace the primacy of direct genetic testing in the diagnosis of GRA.
GRA may be more common in the hypertensive population than had been previously estimated. We encourage those with a clinical and/or family history indicative of GRA to be genetically screened for the disorder. You can access the SCREENING INFORMATION section of this Website or contact Jennifer Higgins-Spiers, the GRA Study Coordinator, directly at 617 732 5066. We welcome any questions about GRA or requests for screening information.
Please email: firstname.lastname@example.org or Erin.Loring@yale.edu for more information
For inquiries about shipping, please contact email@example.com
If you are a health care provider and you need specific information about GRA for your patient, or if you have questions about whether or not you should test for GRA, send inquiries via email to firstname.lastname@example.org and she will get in touch with somebody who can answer your questions.
If you are a parent or patient, and you want information about GRA testing, have primary care doctor or endocrinologist contact Jennifer.
Jennifer does not have medical knowledge of GRA but she is glad to take your questions and help you get answers.
Send Feedback to: Jennifer Higgins-Spiers
This page was last modified on 9/12/2013